MB-WUXI@EC2603A(20893.HK)

Company Encyclopedia

MB-WUXI@EC2603A

20893.HK

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue

Innovent Biologics Inc. reported a 45% year-over-year growth in product revenue for 2025, totaling approximately RMB11.9 billion. In Q4 2025, product revenue reached around RMB3.3 billion, also showing significant growth. The company recognized inventory price adjustments due to the addition of six new drugs to the 2026 National Reimbursement Drug List. This financial information is based on internal records and has not been audited. The original content was published via the Hong Kong Stock Exchange.

Reuters·Yesterday at 18:21

Reuters·Yesterday at 18:21

WuXi Biologics and Vertex Pharma have reached a licensing and research service agreement for innovative tri-specific TCE

WuXi Biologics and Vertex Pharma signed a licensing and research service agreement regarding the innovative trispecific T cell engagers (TCE). Vertex Pharma will obtain the global exclusive development and commercialization rights for the TCE, while WuXi Biologics will receive an upfront payment as well as subsequent milestone payments and sales royalties, and will provide integrated contract research and development services

AASTOCKS·Yesterday at 09:58

AASTOCKS·Yesterday at 09:58

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager | VRTX Stock News

WuXi Biologics has signed a license and research service agreement with Vertex Pharmaceuticals for a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases. Vertex gains exclusive global rights for development and commercialization, while WuXi will receive upfront and milestone payments, along with royalties. This collaboration highlights WuXi's leadership in discovery service solutions and commitment to advancing transformative therapies.

StockTitan·02/03/2026 03:08

StockTitan·02/03/2026 03:08

Hong Kong Stocks Snap Two-Day Slide

Hong Kong stocks rose 111 points (0.4%) to 26,887, ending a two-day decline. The increase followed positive momentum from Wall Street and eased pressure from last week's selloff in metals and cryptocurrencies. Mainland shares also gained, supported by a private survey indicating factory activity growth. However, caution prevailed ahead of Hong Kong's retail sales data and China's VAT increase on telecom services. All sectors saw gains, particularly property and financials, with notable increases in mining stocks and companies like CK Hutchison and Wuxi Biologics.

Trading Economics·02/03/2026 10:22

Trading Economics·02/03/2026 10:22

Wuxi Lead Intelligent Equipment to raise up to $549 million in Hong Kong share sale

marketscreener·02/03/2026 06:48

marketscreener·02/03/2026 06:48

Posts

Hotspot2025.08.14 06:13

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on t...

Hotspot2025.07.11 02:55

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

Hotspot2025.06.27 09:30

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.